Gallbladder Cancer: Integrative and Emerging Therapies Beyond Standard Care

Gallbladder cancer (GBC) is aggressive; standard care (surgery ± chemo) offers limited survival for advanced disease. Integrative and investigational approaches aim to improve outcomes and quality of life.

Complementary Therapies (Symptom Management)

• Acupuncture: RCT evidence for chemotherapy-induced nausea/vomiting, cancer pain, xerostomia.
• Mind-body: MBSR, yoga, tai chi reduce anxiety, fatigue, sleep disturbance.
• Nutrition: Mediterranean diet, omega-3s, protein support during treatment.

Herbal/Traditional Medicine (Preclinical Data)

• Curcumin (turmeric): Inhibits NF-κB, STAT3, angiogenesis in GBC cell lines/xenografts.
• Green tea (EGCG): Pro-apoptotic, anti-metastatic in vitro.
• Milk thistle (silymarin): Hepatoprotective; may modulate chemo-sensitivity.
• Reishi (Ganoderma), Ginseng: Immune modulation; limited GBC-specific data.

Caution: Herb-drug interactions (CYP450) with gemcitabine/cisplatin. Always disclose to oncology team.

Emerging Conventional Therapies

• Immunotherapy: PD-1/PD-L1 inhibitors (pembrolizumab) show activity in MSI-H/dMMR GBC (~5%); trials in biomarker-selected populations.
• Targeted therapy: FGFR2 inhibitors (pemigatinib, futibatinib) for FGFR2 fusions (~10-15% GBC); IDH1 inhibitors (ivosidenib) for IDH1 mutations.
• ADCs: HER2-targeted (trastuzumab deruxtecan) for HER2+ GBC.

Palliative Care Integration

Early palliative care improves symptom control, mood, survival (per Temel et al. model). Includes biliary drainage (stent), pain management, advance care planning.

Clinical Trial Participation

Strongly encouraged for advanced GBC. Search ClinicalTrials.gov for "gallbladder cancer" + molecular markers.